Every 10-Q that Inspiremd (NSPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NSPR filings page.
InspireMD, Inc. reported higher sales but significantly larger losses for the quarter and six months ended June 30, 2026. Revenue was $1.77 million for the quarter (flat year over year) and $5.17 million for the six months, up 56.3%, driven mainly by U.S. commercialization of CGuard Prime and growth in international distributor sales.
A voluntary U.S. recall of the CGuard Prime delivery system weighed heavily on results, including $734,000 of revenue credits and $612,000 of inventory impairment in the quarter, pushing gross margin to −43.7%. Operating expenses remained high, with six‑month R&D of $9.06 million, selling and marketing of $10.40 million, and G&A of $8.88 million, leading to a six‑month net loss of $28.0 million, up 15.2% from 2025.
Cash and cash equivalents were $15.15 million and marketable securities $15.27 million at June 30, 2026, with operating cash outflow of $23.23 million over six months. Management states there is substantial doubt about the company’s ability to continue as a going concern. InspireMD also received a Nasdaq minimum bid price deficiency notice and is pursuing equity, warrant exercises, partnerships and a post‑quarter workforce reduction expected to save about $9 million annually while it works to resolve the recall and advance multiple pivotal trials and FDA submissions.
InspireMD reported sharply higher Q1 2026 revenue but deeper losses and serious liquidity risk. Revenue rose to $3.4 million, up 122% from $1.5 million, driven mainly by the U.S. launch of CGuard Prime and growth in international sales.
Gross margin improved slightly to 20.2%, but operating expenses climbed to $14.7 million as the company expanded U.S. R&D and commercialization. Net loss widened to $13.7 million, and operating cash outflow reached $12.3 million. Cash and marketable securities totaled $41.6 million at quarter end.
The company disclosed a voluntary U.S. recall of its CGuard Prime 135 cm delivery system, with estimated reserves of about $700,000 for customer returns and $650,000 for inventory impairment and remediation. Management states there is substantial doubt about its ability to continue as a going concern without additional capital, and highlights ongoing geopolitical risks tied to its Israeli manufacturing base.
InspireMD (NSPR) filed its Q3 2025 10‑Q, highlighting the first U.S. sales of CGuard Prime after FDA PMA approval in June and a July commercial launch. Revenue rose to $2.523 million from $1.810 million a year ago as U.S. direct sales began and international distributor sales grew. Gross profit improved to $864,000 from $414,000, with gross margin up to 34.2%.
Operating investments to build U.S. commercialization drove higher expenses: R&D $3.635 million, S&M $4.392 million, and G&A $5.888 million. Net loss widened to $12.708 million (loss per share $0.17) versus $7.890 million last year.
Liquidity strengthened from financings and warrant exercises. Cash and cash equivalents were $63.403 million at September 30, 2025. The company closed a private placement with roughly $40.1 million in gross proceeds and received $16.9 million net from Series I warrant exercises. Despite this, management disclosed substantial doubt about the ability to continue as a going concern given expected operating losses until commercial profitability. Shares outstanding were 41,919,141 as of September 30, 2025; 42,370,995 as of November 10, 2025.